SAN ANTONIO — Oxybutynin significantly reduced the frequency and severity of hot flashes among breast cancer survivors, according to results of the randomized controlled ACCRU SC-1603 study presented at San Antonio Breast Cancer Symposium.

“Hot flashes are a significant problem across the general population, but even more so among breast cancer survivors,” Roberto A. Leon-Ferre, MD, assistant professor of oncology at the Mayo Clinic in Rochester, Minnesota, said during a press conference. “Hot flashes may affect up to 75% of midlife women and can persist for more than 15 years. It is no surprise that hot flashes can negatively impact patients’ quality of life, interfering with work, sleep and relationships.”